Who owns Corbus Pharmaceuticals Holdings, Inc. (CRBP)? Elite investor 13F holders
2 tracked elite investors reported holding Corbus Pharmaceuticals Holdings, Inc as of 2026-06-30, including Renaissance Technologies LLC, Ancora Advisors / Ancora Holdings. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Renaissance Technologies LLC | CORBUS PHARMACEUTICALS HLDGS | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 1039510.00 USD | 110822.000000 | Shares | reduce | Original filing |
| D.E. Shaw | CORBUS PHARMACEUTICALS HLDGS | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
| Ancora Advisors / Ancora Holdings | CORBUS PHARMACEUTICALS HLDGS | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 600.00 USD | 64.000000 | Shares | hold | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.